Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2020

View Archived Issues

Encouraging preliminary phase I data announced for VAC-2 in NSCLC

Mucolytic agent MUC-031 has beneficial effects in cystic fibrosis model

Boehringer and OBT expand collaboration to discover additional selective cancer targets

Copanlisib plus rituximab leads to significantly prolonged PFS in CHRONOS-3 study

Phase III ASTRAL-2 and ASTRAL-3 studies of guadecitabine do not meet primary endpoint

FDA transfers IND application OST-HER2 to OS Therapies

FDA clears IND to initiate phase Ib/IIa study of AP-PA02

Positive data from ILIAD study of peginterferon lambda in outpatients with COVID-19

Ono Pharmaceutical synthesizes bispecific antibodies targeting CD19 and PD-1

New Toll-like receptor 2 antagonists identified at Neuropore Therapies

University of Barcelona discovers soluble epoxide hydrolase and acetylcholinesterase inhibitors

New pantothenate kinase 3 inhibitors identified at St. Jude Children's Research Hospital

Genfleet Therapeutics patents RIP-1 inhibitors

Investigator-initiated study of IONIS-PKK-LRx in patients with COVID-19 begins

Phase II trial of GLPG-1972 in osteoarthritis does not meet primary objective

MRT-5500 elicits neutralizing antibodies against SARS-CoV-2 in vivo

Unite and conquer approach finds shared weaknesses of coronaviruses

Vorinostat + sirolimus or everolimus shows encouraging activity and safety in r/r Hodgkin's lymphoma

BP-C2 mitigates radiation-induced gastrointestinal syndrome in mice

The cross-talk of SNAI2 and Hippo pathway in breast cancer metastasis

Exonate cleared to begin phase Ib/II evaluation of EXN-407 for diabetic macular edema

FDA approves Keytruda for adults with relapsed or refractory classical Hodgkin's lymphoma

Chitinase-3-like protein 1 identified as cystic fibrosis therapeutic target

Arch begins phase II trial of LSALT to prevent COVID-19-related complications

ImmunityBio receives FDA clearance for phase I trial of hAd5-COVID-19

FDA accepts IND for phase I/II study of Nuvation's NUV-422 in high-grade gliomas

Popular Stories

23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Today's news in brief
BioWorld
BioWorld briefs for June 18, 2025.
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 18, 2025.
EACR 2025: Immune rewiring in cancer orchestrates tumor microenvironment
BioWorld Science
Among the presentations included in the Top Abstracts category at the recently inaugurated Annual Congress of the European Association for Cancer Research (EACR)...